AAV-based CRISPR-Cas9 genome editing: Challenges and engineering opportunities
Authors:
- Ami M. KabadiAKAmi M. Kabadi
- Maria Katherine Mejia-GuerraMMMaria Katherine Mejia-Guerra
- John D. GraefJGJohn D. Graef
- Sohrab Z. KhanSKSohrab Z. Khan
- Eric M. WaltonEWEric M. Walton
- Xinzhu WangXWXinzhu Wang
- Charles A. GersbachCGCharles A. Gersbach
- Rachael PotterRPRachael Potter
Open Access
- 7 December 2023
- journal article
- research article
- Published by Elsevier in Current Opinion in Biomedical Engineering
- Vol. 29
Abstract
No abstract availableKeywords
Funding Information
- Sarepta Therapeutics
This publication has 66 references indexed in Scilit:
- Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas SystemCell, 2015
- In vivo genome editing using Staphylococcus aureus Cas9Nature, 2015
- Inducible in vivo genome editing with CRISPR-Cas9Nature Biotechnology, 2015
- Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidisProceedings of the National Academy of Sciences, 2013
- Multiplex Genome Engineering Using CRISPR/Cas SystemsScience, 2013
- Engineering Liver-detargeted AAV9 Vectors for Cardiac and Musculoskeletal Gene TransferMolecular Therapy, 2011
- In Vitro and In Vivo Gene Therapy Vector Evolution via Multispecies Interbreeding and Retargeting of Adeno-Associated VirusesJournal of Virology, 2008
- Directed evolution of adeno-associated virus yields enhanced gene delivery vectorsNature Biotechnology, 2006
- Generation of a synthetic mammalian promoter library by modification of sequences spacing transcription factor binding sitesGene, 2002
- Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogsNucleic Acids Research, 2001